F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal ArticleDOI
Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
Nicolai J. Wewer Albrechtsen,Simon Veedfald,Astrid Plamboeck,Carolyn F. Deacon,Bolette Hartmann,Filip K. Knop,Tina Vilsbøll,Jens J. Holst +7 more
TL;DR: It is demonstrated that the most advanced approach is not necessarily the best when measuring a low-abundant peptide such as glucagon in humans, even when state-of-the-art immune-based technologies are used.
Journal ArticleDOI
EJE PRIZE 2018: A gut feeling about glucagon
TL;DR: The hypothesis that steatosis-induced hepatic glucagon resistance (and reduced amino acid turnover) and compensatory glucagon secretion mediated by increased circulating amino acids constitute a complete endocrine feedback system: the liver-alpha cell axis is considered.
Journal ArticleDOI
Adult atopic dermatitis and the risk of type 2 diabetes
Yuki M.F. Andersen,Alexander Egeberg,Gunnar Gislason,Lone Skov,Filip K. Knop,Jacob P. Thyssen +5 more
Journal ArticleDOI
No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
Natasha C. Bergmann,Lærke S. Gasbjerg,Sebastian M. Nguyen Heimbürger,Liva S.L. Krogh,Flemming Dela,Bolette Hartmann,Jens J. Holst,Lene Jessen,Mikkel B. Christensen,Tina Vilsbøll,Tina Vilsbøll,Asger Lund,Filip K. Knop +12 more
TL;DR: In patients with type 2 diabetes, GIP infusion on top of treatment with metformin and a long-acting GLP-1R agonist did not affect energy intake, appetite, or energy expenditure but increased plasma glucose compared with placebo, indicating no acute beneficial effects of combining GIP and GLP -1.
Journal ArticleDOI
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons.
TL;DR: Describing data indicate that individual GLP‐1RAs affect CV risk factors differently, potentially because of their individual pharmacokinetics and/or size.